The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia

Leukemia and Lymphoma

Volumn 46, Issue 6, 2005, Pages 795-802

  Fassas, Athanasios ^a   Anagnostopoulos, Achilles ^a  

^a G PAPANICOLAOU HOSPITAL   (Greece)

Author keywords

Acute myeloid leukemia; DaunoXome; Liposomal daunorubicin

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BLEOMYCIN; CHOLESTEROL; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; DAUNORUBICINOL; DISTEAROYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; LIPOSOME; THALIDOMIDE; TOPOTECAN; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CLINICAL TRIAL; CYTOTOXICITY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; DRUG TRANSFORMATION; DRUG TUMOR LEVEL; ENCAPSULATION; GLIOMA; HEART DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; KAPOSI SARCOMA; LIVER DISEASE; MAXIMUM TOLERATED DOSE; META ANALYSIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIDRUG RESISTANCE; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSPECTIVE STUDY; REVIEW; STEM CELL TRANSPLANTATION; SYSTEMATIC REVIEW; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; CYTARABINE; DAUNORUBICIN; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION;

EID: 21844468233     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500052438     Document Type: Review

References (48)

1. Rahman A, Treat J, Roh JK, et al. A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol 1990;8:1093-1100.
2. Forssen EA, Coulter DM, Proffitt RT. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res 1992;52:3255-3261.
3. Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 1992;52:891-896.
4. Forssen EA, Male-Brune R, Adler-Moore JP et al. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. Cancer Res 1996;56:2066-2075.
5. Pouna P, Bonoron-Adele S, Gouverneur G, Tariosse L, Besse P, Robert J. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Br J Pharmacol 1996;117:1593-1599.
6. Wang Y, Eksborg S, Lewensohn R, Lindberg A, Liliemark E. In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells. Anticancer Drugs 1999;10:921-928.
7. 2. Ann Oncol 2000; 11:1029-1033.
8. Safra T. Cardiac safety of liposomal anthracyclines. Oncologist 2003;8(Suppl. 2):17-24.
9. Gill PS, Espina BM, Muggia F et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 1995;13:996-1003.
10. Pea F, Russo D, Michieli M et al. Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia. Cancer Chemother Pharmacol 2000;46:279-286.
11. Rahman A, White G, More N, Schein PS. Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes. Cancer Res 1985;45:796-903.
12. Verdonck LF, Lokhorst HM, Roovers DJ, van Heugten HG. Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: implications for liposome-encapsulated daunorubicin. Leuk Res 1998;22:249-256.
13. Sargent JM, Elgie AW, Williamson CJ, Lewandowitz GM, Taylor CG. In vitro sensitivity to the liposomal preparation, DaunoXome in CLL. Anticancer Res 1999;19:3253-3257.
14. Harris L, Batist G, Belt R et al.; TLC D-99 Study Group. Liposome encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002;94:25-36.
15. Batist G, Ramakrishnan G, Rao CS et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001;19:1444-1454.
16. O'Brien ME, Wigler N, Inbar M et al.; CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-449.
17. Forssen EA, Ross ME. DaunoXome treatment of solid tumors: preclinical and clinical investigations. J Liposome Res 1994;4:481-512.
18. Hempel G, Reinhardt D, Creutzig U, Boos J. Population pharmacokinetics of liposomal daunorubicin in children. Br J Pharmacol 2003;56:370-377.
19. Belott R, Auvrignon A, Leblanc T et al. Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I/II study in children with relapsed acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2001;47:15-21.
20. Pea F, Russo D, Michieli M et al. Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukemia. Clin Pharmacokinet 2003;42:851-862.
21. Michieli M, Damiani D, Ermacora A et al. Liposome encapsulated daunorubicin for PGP-related multidrug resistance. Br J Haematol 1999;106:92-99.
22. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 2000;6:1949-1957.
23. Ni S, Stephenson SM, Lee RJ. Folate receptor targeted delivery of liposomal daunorubicin into tumor cells. Anticancer Res 2002;22:2131-2135.
24. Berry G, Billingham M, Alderman E et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998;9:711-716.
25. Lin FT, Kelsey SM, Newland AC, Jia L. Liposomal encapsulation diminishes daunorubicin-induced generation of reactive oxygen species, depletion of ATP and necrotic cell death in human leukemic cells. Br J Haematol 2002;117:333-342.
26. Shacter E, Williams JA, Hinson RM, Senturker S, Lee YJ. Oxidative stress interferes with cancer chemotherapy: inhibition of lymphoma cell apoptosis and phagocytosis. Blood 2000;96:307-313.
27. Gill PS, Wernz J, Scadden DT et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996;14:2353-2364.
28. O'Byrne KJ, Thomas AL, Sharma RA et al. A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. Br J Cancer 2002;87:15-20.
29. Cortes JE, Fassas A, Anagnostopoulos A et al. Liposomal daunorubicin (DaunoXome) has minimal cardiotoxicity in patients with prior anthracycline therapy for acute myeloid leukemia. Blood 1999;94:508a.
30. Todeschini G, Tecchio C, Meneghini V et al. Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin. Leukemia 1998;12:144-149.
31. Head D, Kopecky KJ, Weick J et al. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 1995;86:1717-1728.
32. Rees JK, Gray RG, Wheatley K. Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party. Br J Haematol 1996;94:89-98.
33. Usui N, Dobashi N, Kobayashi T et al. Role of daunorubicin in the induction therapy for adult acute myeloid leukemia. J Clin Oncol 1998;16:2086-2092.
34. Cortes J, O'Brien S, Estey E, Giles F, Keating M, Kantarjian H. Phase I study of liposomal daunorubicin in patients with acute leukemia. Invest New Drugs 1999;17:81-87.
35. Ermacora A, Michieli M, Pea F, Visani G, Bucalossi A, Russo D. Liposome encapsulated daunorubicin (daunoxome) for acute leukemia. Haematologica 2000;85:324-425.
36. Bieker R, Lerchenmüller C, Wehmeyer J et al. Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia. Oncol Rep 2003;10:915-920.
37. Fassas A, Buffels R, Anagnostopoulos A et al. Safety and early efficacy assessment of liposomal daunorubicin (daunoxome) in adults with refractory or relapsed acute myeloblastic leukemia: a phase I-II study. Br J Haematol 2002;11 6:308-315.
38. Fassas A, Buffels R, Kaloyannidis P, Anagnostopoulos A. Safety of high dose liposomal daunorubicin (daunoxome) for refractory or relapsed acute myeloblastic leukaemia. Br J Haematol 2003;122:161-162.
39. Cortes J, Estey E, O'Brien S et al. High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer 2001;92:7-14.
40. Russo D, Piccaluga PP, Michieli M et al. Liposomal daunorubicin (daunoxome) for treatment of poor-risk acute leukemia. Ann Hematol 2002;81:462-466.
41. Reinhardt D, Hempel G, Fleischhack G, Schutz A, Boos J, Creutzig U. Effektive Redizivtherapie der akuten myeloischen Leukämie im Kindesalter mit liposomalem. Daunorubicin und Cytarabin. Kim Pädiatr 2002;214:188-194.
42. Clavio M, Venturino C, Pierri I et al. Combination of liposomal daunorubicin (daunoxome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. Ann Hematol 2004;83:696-703.
43. Tökés ZA, St. Peteri AK, Todd JA. Availability of liposome content to the nervous system. Liposomes and the blood-brain barrier. Brain Res 1980;188:282-286.
44. Lippens RJ. Liposomal daunorubicin (daunoxome) in children with recurrent or progressive brain tumors. Pediatr Hematol Oncol 1999;16:131-139.
45. Zucchetti M, Boiardi A, Silvani A, Parisi I, Piccolrovazzi S, D'Incalci M. Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin. Cancer Chemother Pharmacol 1999;44:173-176.
46. Piccaluga PP, Visani G, Martinelli G et al. Liposomal daunorubicin (daunoxome) for treatment of relapsed meningeal acute myeloid leukemia. Leukemia 2002;16:1880-1881.
47. Cortes J, Kantarjian H, Albitar M et al. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2001;97:1234-1241.
48. Apostolidou E, Cortes J, Tsimberidou A, Estey E, Kantarjian H, Giles F. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res 2003;27:887-891.